Moderna, Inc.(MRNA)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
MRNA | 96.65 B | - | 2.10% | -141.43% | -$7.98 | -39.00% | 0.19x | 0.00% | $243.98 | $22.28 |
ABBV | 510.84 B | 81.66x | 10.20% | 9.80% | $3.54 | - | - | 2.36% | $291.40 | $188.25 |
AMGN | 237.31 B | 27.26x | 9.50% | 22.95% | $16.10 | 91.47% | 4.90x | 2.23% | $447.03 | $280.23 |
GILD | 194.07 B | - | 10.20% | -10.64% | -$2.65 | -20.68% | 2.23x | 2.06% | $160.51 | $111.27 |
950220.KQ | 57.50 B | - | 4559.30% | 0.00% | - | -61.03% | 0.20x | - | $4450.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for Moderna, Inc. (MRNA) compared to its primary competitors (including ABBV, AMGN, GILD) reveals distinct metrics. MRNA trades at a valuation discount relative to its competitors, with a P/E ratio of -30.3x versus the peer average of 16.6x (representing a 283% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, MRNA's revenue growth of 2.1% lags behind the peer average of 1147.3%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -141.4% is below the peer average of 5.5%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• MRNA ranks #0 in P/E ratio, #5 in revenue growth, and #5 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $226.03 | $243.98 | $216.65 | $242.08 | 16,796,983 | +6.69% |
| 2026-10-19 | $217.27 | $236.77 | $216.00 | $226.89 | 18,788,900 | +4.07% |
| 2026-10-16 | $235.00 | $237.96 | $208.92 | $218.01 | 21,403,300 | -7.82% |
| 2026-10-15 | $225.48 | $242.29 | $217.02 | $236.50 | 17,313,500 | +4.51% |
| 2026-10-14 | $217.49 | $227.09 | $211.24 | $226.30 | 16,625,400 | +4.65% |
| 2026-10-13 | $207.63 | $218.48 | $204.70 | $216.25 | 13,389,300 | +1.17% |
| 2026-10-12 | $224.50 | $227.46 | $210.91 | $213.74 | 12,873,900 | -5.00% |
| 2026-10-09 | $199.00 | $225.00 | $197.17 | $225.00 | 28,947,300 | +14.21% |
| 2026-10-08 | $196.42 | $199.92 | $192.71 | $197.00 | 37,400,000 | +0.26% |
| 2026-10-07 | $183.65 | $197.69 | $182.50 | $196.48 | 14,640,200 | +4.81% |
| 2026-10-06 | $202.09 | $212.22 | $186.64 | $187.46 | 18,794,800 | -7.75% |
| 2026-10-05 | $191.41 | $205.77 | $185.90 | $203.21 | 19,313,300 | +6.95% |
| 2026-10-02 | $190.26 | $193.72 | $183.28 | $190.01 | 10,289,500 | +0.57% |
| 2026-10-01 | $186.61 | $201.00 | $186.01 | $188.94 | 15,437,000 | -1.89% |
| 2026-09-30 | $186.55 | $196.83 | $184.58 | $192.57 | 20,649,500 | -5.35% |
Explore More Analysis for MRNA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.